INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of The Chemours Company - CC

2026-03-03 04:16:22

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company (“Chemours” or the“Company”) (NYSE: CC). Such investors are advised to contact Danielle Peyton at ... or 646-581-9980, ext. 7980.

The investigation concerns whether Chemours and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On February 19, 2026, Chemours reported its fourth quarter and full year 2025 financial results. Among other items, Chemours disclosed that 2025 EBITDA was negatively affected by a one-time inventory charge in its Advanced Performance Materials segment, which the Company said was experiencing“short-term cyclical end market headwinds[.]”

On this news, Chemours's price fell $3.37 per share, or 16.51%, to close at $17.04 per share on February 20, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See .

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
...
646-581-9980 ext. 7980

MENAFN03032026004107003653ID1110814306

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.